Publikationsliste Psychopharmaka: Studien zu Antidepressiva, Benzodiazepinen, Neuroleptika, Phasenprophylaktika

[Team PsyAb]

Hier eine Liste von Publikationen, die zum Thema Psychopharmaka, Wirksamkeit, Risiken, Nebenwirkungen, Absetzen und Entzugssyndrom relevant sind.
Der älteste Teil wurde vom adfd.org übernommen und aktualisiert. Die Liste wird fortlaufend ergänzt.

Die Liste ist nach Jahreszahlen geordnet, darunter alphabetisch nach den Erstautoren.

Zuletzt ergänzt am 31.03.2025



2025

Baranova, A., Liu, D., Sun, W., Xu, C., Chen, M., Cao, H. & Zhang, F. (2025): Antidepressants account for the causal effect of major depressive disorder on type 2 diabetes. Progress in Neuro-Psychopharmacology and Biological Psychiatry,136, 111164 https://doi.org/10.1016/j.pnpbp.2024.111164

ESC Press releases (2025): Use of antidepressant medication linked to substantial increase in risk of sudden cardiac death (Vienna, Austria- 30 March 2025), European Society of Cardiology https://www.escardio.org/The-ESC/Press- ... diac-death

Ferraro MC, Urquhart DM, Ferreira GE, Wewege MA, Abdel Shaheed C, Traeger AC, Hoving JL, Visser EJ, McAuley JH, Cashin AG (2025): Antidepressants for low back pain and spine‐related leg pain. Cochrane Database of Systematic Reviews 2025, Issue 3. Art. No.: CD001703. https://doi.org/10.1002/14651858.CD001703.pub4

Gründer, G., Mertens, L.J., Spangemacher, M. et al. (2025): Können Antidepressiva den langfristigen Verlauf depressiver Erkrankungen negativ verändern?. Nervenarzt 96, 146–152 (2025). https://doi.org/10.1007/s00115-025-01801-1

Mo, M., Abzhandadze, T., Hoang, M.T. et al.(2025): Antidepressant use and cognitive decline in patients with dementia: a national cohort study. BMC Med 23, 82 (2025). https://doi.org/10.1186/s12916-025-03851-3

Rajha, H. E., Abdelaal, R., Charfi, K., Alemadi, A. O., Al-Sheraim, A. S., Al-Maadid, M. A., Louati, Y., Doi, S., & Khaled, S. M. (2025): Examining depression, antidepressants use, and class and their potential associations with osteoporosis and fractures in adult women: Results from ten nhanes cohorts. Journal of Affective Disorders, 369, 1223-1232
https://doi.org/10.1016/j.jad.2024.10.114

Wand, T. (2025): Examining the Long-Term Impacts of Psychotropic Drugs and Considerations for People Discontinuing Treatment. Issues in Mental Health Nursing, 1–9. https://doi.org/10.1080/01612840.2025.2476156

Zhang, Y., Gao, Y., Li, X. et al.(2025): Antidepressant treatment of depression in children and adolescents: a systematic review and dose-response meta-analysis. Eur Child Adolesc Psychiatry (2025). https://doi.org/10.1007/s00787-025-02688-8


2024

Boland M, Higgins A, Beecher C, et al (2024): Identifying priorities for future research on reducing and stopping psychiatric medication: results of a James Lind Alliance priority-setting partnership, BMJ Open 2024;14:e088266.
https://doi.org/10.1136/bmjopen-2024-088266

Brisnik, V., Rottenkolber, M., Vukas, J. et al. (2024): Potential deprescribing indications for antidepressants between 2012 and 2019: repeated cross-sectional analysis in two Scottish health boards. BMC Med 22, 378 (2024). https://doi.org/10.1186/s12916-024-03584-9

Coe Amy, Abid Noor, Kaylor-Hughes Catherine (2024): Social media group support for antidepressant deprescribing: a mixed-methods survey of patient experiences. Australian Journal of Primary Health 30, PY23046. https://doi.org/10.1071/PY23046

Desaunay Pierre, Maxime, Alexandre Joachim, Dreyfus Michel, Chrétien Basile, Guénolé Fabian(2024): Antidepressants and fetal death: A systematic review and disproportionality analysis in the WHO safety database (VigiBaseⓇ),Psychiatry Research, Volume 339, 2024,116048,
https://doi.org/10.1016/j.psychres.2024.116048

Gibbons RD, Hur K, Lavigne JE, Mann JJ (2024): Risk of suicide attempts and intentional self-harm on alprazolam. Psychiatry Res. 2024 May;335:115857. doi: 10.1016/j.psychres.2024.115857. Epub 2024 Mar 11. PMID: 38493738.
https://doi.org/10.1016/j.psychres.2024.115857

Horowitz, Mark A., Moncrieff Joanna, (2024): Gradually tapering off antipsychotics: lessons for practice from case studies and neurobiological principles. Current Opinion in Psychiatry 37(4):p 320-330, July 2024. | DOI: 10.1097/YCO.0000000000000940

Luykx JJ, Correll CU, Manu P, et al. (2024): Pneumonia Risk, Antipsychotic Dosing, and Anticholinergic Burden in Schizophrenia. JAMA Psychiatry. 2024;81(10):967–975. doi:10.1001/jamapsychiatry.2024.1441

Mahmood R, Wallace V, Wiles N, Kessler D, Button KS, Fairchild G. (2024): The lived experience of withdrawal from Selective Serotonin Reuptake Inhibitor (SSRI) antidepressants: a qualitative interview study. Health Expect. 2024; 27:e13966.
https://doi.org/10.1111/hex.13966

Maviglia M, Hume D, Cooeyate NJ (2024): Kindling in psychopharmacology: Unveiling an overlooked clinical challenge with significant implications. J Psychol Clin Psychiatry. 2024;15(5):282-290. DOI: 10.15406/jpcpy.2024.15.00793

Mok P L H, Carr M J, Guthrie B, Morales D R, Sheikh A, Elliott R A et al.(2024): Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study BMJ 2024; 385 :e076268 doi:10.1136/bmj-2023-076268

Moncrieff Joanna, Read John, Horowitz Mark Abie (2024): The nature and impact of antidepressant withdrawal symptoms and proposal of the Discriminatory Antidepressant Withdrawal Symptoms Scale (DAWSS),
Journal of Affective Disorders Reports,Volume 16, 2024,
https://doi.org/10.1016/j.jadr.2024.100765.

Read, J. (2024): What is helpful and unhelpful when people try to withdraw from antipsychotics: An international survey. Psychology and Psychotherapy: Theory, Research and Practice, 97, 665–685. https://doi.org/10.1111/papt.12551

Storck W, de Laportalière TT, Yrondi A, Javelot H, Berna F, Montastruc F. (2024): Withdrawal syndrome after antipsychotics discontinuation: an analysis of the WHO database of spontaneous reports (Vigibase) between 2000 and 2022. Psychopharmacology (Berl). 2024 Jun;241(6):1205-1212. Epub 2024 Feb 20. PMID: 38376511. doi: 10.1007/s00213-024-06554-4.

Taipale H, Tanskanen A, Kurko T, et al. (2024): Long-term benzodiazepine use and risk of labor market marginalization in Finland: A cohort study with 5-year follow-up. European Psychiatry. 2024;67(1):e34. doi:10.1192/j.eurpsy.2024.1745

Wecker, S. N., Dammert, A. S., Scholz, C., Krüger, M., Hauer, J., & Brickmann, C. (2024): Neonatal therapy after maternal central neurotropic drug exposure—a retrospective cohort study. The Journal of Maternal-Fetal & Neonatal Medicine, 37(1)
doi.org/10.1080/14767058.2024.2356038

Wunderink L. (2024): Changing vistas of psychosis and antipsychotic drug dosing toward personalized management of antipsychotics in clinical practice. Psychiatr Rehabil J. 2024 Dec;47(4):322-328. Epub 2024 Apr 22. PMID: 38647464. doi: 10.1037/prj0000614

Zhang MM, Tan X, Zheng YB, Zeng N, Li Z, Horowitz MA, Feng XZ, Wang K, Li ZY, Zhu WL, Zhou X, Xie P, Zhang X, Wang Y, Shi J, Bao YP, Lu L, Li SX (2024): Incidence and risk factors of antidepressant withdrawal symptoms: a meta-analysis and systematic review. Mol Psychiatry. 2024 Oct 11. doi: 10.1038/s41380-024-02782-4.

Zhao Y, Zhang Y, Yang L, Zhang K, Li S.(2024): Safety Profile of Selective Serotonin Reuptake Inhibitors in Real-World Settings: A Pharmacovigilance Study Based on FDA Adverse Event Reporting System. Annals of Pharmacotherapy. 2024;58(11):1105-1116. https://doi.org/10.1177/10600280241231116

[Team PsyAb]

2023

Al-Wandi, A., Landén, A. M., & Nordenskjöld, A. (2023): Antipsychotics in the maintenance phase for psychotic depression. Acta Psychiatrica Scandinavica, November 6, 2023. https://doi.org/10.1111/acps.13628

Andrianopoulou E.T., Galanis P., Alevizopoulos G. (2023): The effect of antipsychotic treatment, during the perinatal period, on the neurodevelopment of children: a systematic review and meta-analysis, October 2023, https://doi.org/10.21203/rs.3.rs-3436752/v1

Bergström Tomi, Gauffin Tapio, (2023): The Association of Antipsychotic Postponement With 5-Year Outcomes of Adolescent First-Episode Psychosis, Schizophrenia Bulletin Open, Volume 4, Issue 1, January 2023, sgad032, https://doi.org/10.1093/schizbullopen/sgad032

Birkinshaw H, Friedrich CM, Cole P, Eccleston C, Serfaty M, Stewart G, White S, Moore RA, Phillippo D, Pincus T. (2023): Antidepressants for pain management in adults with chronic pain: a network meta‐analysis. Cochrane Database of Systematic Reviews 2023, Issue 5. Art. No.: CD014682. DOI: 10.1002/14651858.CD014682.pub2.

Cooper Ruth E., Ashman Michael ,Lomani Jo, Moncrieff Joanna, Guy Anne, Davies James, Morant Nicola, Horowitz Mark, (2023): “Stabilise-reduce, stabilise-reduce”: A survey of the common practices of deprescribing services and recommendations for future services, https://doi.org/10.1371/journal.pone.0282988

Cuijpers, P., Miguel, C., Harrer, M., Plessen, C.Y., Ciharova, M., Ebert, D. and Karyotaki, E. (2023): Cognitive behavior therapy vs. control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression: a comprehensive meta-analysis including 409 trials with 52,702 patients. World Psychiatry, 22: 105-115. https://doi.org/10.1002/wps.21069

Davies J, Read J, Kruger D, Crisp N, Lamb N, Dixon M et al. (2023): Politicians, experts, and patient representatives call for the UK government to reverse the rate of antidepressant prescribing BMJ 2023; 383 :p2730 doi:10.1136/bmj.p2730

Fornaro, M., Cattaneo, C. I., De Berardis, D., Ressico, F. V., Martinotti, G., & Vieta, E. (2023): Antidepressant discontinuation syndrome: A state-of-the-art clinical review. European Neuropsychopharmacology, 66, 1-10. https://doi.org/10.1016/j.euroneuro.2022.10.005

Hansen L. (2023): Fluoxetine Dose-Increment Related Akathisia in Depression: Implications for Clinical Care, Recognition and Management of Selective Serotonin Reuptake Inhibitor-Induced Akathisia. Journal of Psychopharmacology. 2003; 17(4):451-452. https://doi.org/10.1177/0269881103174003

Horowitz MA, Taylor D (2023): Addiction and physical dependence are not the same thing. The Lancet Psychiatry, Volume 10, Issue 8, e23 https://doi.org/10.1016/S2215-0366(23)00230-4

Huff C, Finlayson AJR, Foster DE, Martin PR. (2023): Enduring neurological sequelae of benzodiazepine use: an Internet survey. Therapeutic Advances in Psychopharmacology. 2023;13. https://doi.org/10.1177/20451253221145561

Hvidberg, M. F. (2023): Are antidepressants effective in the treatment of depression in the elderly? A critical umbrella review on reviews, methods, and future perspectives. Mental Health Science, 1(2), 85-103. https://doi.org/10.1002/mhs2.14

Khan, Y. S., Khoodoruth, M. A. S., Albobali, Y., & Haddad, P. M. (2023): SSRI withdrawal syndrome in children and adolescents: a narrative literature review. Expert Opinion on Drug Safety, 22(5), 381–390. https://doi.org/10.1080/14740338.2023.2224557

Koc, D., Tiemeier, H., Stricker, B. H., Muetzel, R. L., Hillegers, M., & El Marroun, H. (2023). Prenatal antidepressant exposure and offspring brain morphologic trajectory. JAMA Psychiatry, August 30, 2023. doi:10.1001/jamapsychiatry.2023.3161

Lagerberg, T., Matthews, A.A., Zhu, N. et al.(2023): Effect of selective serotonin reuptake inhibitor treatment following diagnosis of depression on suicidal behaviour risk: a target trial emulation. Neuropsychopharmacol. 48, 1760–1768 (2023). https://doi.org/10.1038/s41386-023-01676-3

Lakshmi N. Yatham, Shyam Sundar Arumugham, Muralidharan Kesavan, Kanchana Ramachandran, Nithyananda S. Murthy, Gayatri Saraf, Yongdong Ouyang, (2023): Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression, N Engl J Med 2023;389:430-440
DOI: 10.1056/NEJMoa2300184

Langley, C., Armand, S., Luo, Q., Savulich, G., Segerberg, T., Søndergaard, A., . . . & Sahakian, B. J. (2023): Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomized study. Neuropsychopharmacology. https://doi.org/10.1038/s41386-022-01523-x

Lehmann, P. (2023): Gibt es eine Abhängigkeit von Antidepressiva und Neuroleptika? Wem nützt welche Antwort? Und was folgt daraus für die Praxis? https://www.researchgate.net/publicatio ... die_Praxis

Maß, R., Backhaus, K., Lohrer, K. et al. (2023): No benefit of antidepressants in inpatient treatment of depression. A longitudinal, quasi-experimental field study. Psychopharmacology (2023). https://doi.org/10.1007/s00213-023-06417-4

Palmer, E. G., Sornalingam, S., Page, L., & Cooper, M. (2023): Withdrawing from SSRI antidepressants: Advice for primary care. British Journal of General Practice, 73(728), 138-140. DOI: https://doi.org/10.3399/bjgp23X732273

Read, J. (2023): Findings from a survey of 530 British antidepressant users -Antidepressant users report urgent need for services to assist with withdrawal. Psychology today, September 15, 2023 https://www.psychologytoday.com/us/blog ... 30-british

Read, J., Lewis, S., Horowitz, M., & Moncrieff, J. (2023). The need for antidepressant withdrawal support services: Recommendations from 708 patients. Psychiatry Research, 326, 115303. https://doi.org/10.1016/j.psychres.2023.115303

Read J, Moncrieff J ,Horowitz MA, (2023). Designing withdrawal support services for antidepressant users: Patients’ views on existing services and what they really need, Journal of Psychiatric Research, Volume 161, 2023, Pages 298-306, ISSN 0022-3956,
https://doi.org/10.1016/j.jpsychires.2023.03.013.

Ritvo AD, Foster DE, Huff C, Finlayson AJR, Silvernail B, Martin PR, (2023): Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey. PLoS ONE 18(6): e0285584. https://doi.org/10.1371/journal.pone.0285584

Schlier, Björn et al. (2023): Time-dependent effect of antipsychotic discontinuation and dose reduction on social functioning and subjective quality of life–a multilevel meta-analysis, eClinicalMedicine, Volume 65, 102291 DOI: 10.1016/j.eclinm.2023.102291

van Os, J., & Groot, P. C. (2023): Outcomes of hyperbolic tapering of antidepressants. Therapeutic Advances in Psychopharmacology, May 9, 2023. https://doi.org/10.1177/20451253231171518



2022

Almohammed OA, Alsalem AA, Almangour AA, Alotaibi LH, Al Yami MS, et al. (2022): Antidepressants and health-related quality of life (HRQoL) for patients with depression: Analysis of the medical expenditure panel survey from the United States. PLOS ONE 17(4): e0265928. https://doi.org/10.1371/journal.pone.0265928

Ang, B., Horowitz, M., Moncrieff, J. (2022): Is the chemical imbalance an ‘urban legend’? An exploration of the status of the serotonin theory of depression in the scientific literature, SSM - Mental Health, Volume 2, 2022,100098, ISSN 2666-5603,
https://doi.org/10.1016/j.ssmmh.2022.100098.

Arnone D, Hansen L, Kerr JS. (2022): Acute dystonic reaction in an elderly patient with mood disorder after titration of paroxetine: possible mechanisms and implications for clinical care. Journal of Psychopharmacology. 2002;16(4):395-397. https://doi.org/10.1177/026988110201600418

Bansal N, Hudda M, Payne RA, Smith DJ, Kessler D, Wiles N. (2022): Antidepressant use and risk of adverse outcomes: population-based cohort study. BJPsych Open. 2022;8(5):e164. doi:10.1192/bjo.2022.563

Erken N, Kaya D, Dost FS, Ates Bulut E, Isik AT. (2022): Antidepressant-induced serotonin syndrome in older patients: a cross-sectional study. Psychogeriatrics. 2022 Jul;22(4):502-508. doi: 10.1111/psyg.12849. Epub 2022 May 13. PMID: 35562169.

Gallo AT, Hulse GK (2022): Hyperbolic dose reduction of escitalopram mitigates withdrawal syndrome: A case report, Psychiatry Research Case Reports,Volume 1, Issue 1, 2022,100009, ISSN 2773-0212, https://doi.org/10.1016/j.psycr.2022.100009.

Gastaldon, C., Schoretsanitis, G., Arzenton, E. et al. (2022): Withdrawal Syndrome Following Discontinuation of 28 Antidepressants: Pharmacovigilance Analysis of 31,688 Reports from the WHO Spontaneous Reporting Database. Drug Saf 45, 1539–1549 (2022).
https://doi.org/10.1007/s40264-022-01246-4

Ghaemi, S. N. (2022): Symptomatic versus disease-modifying effects of psychiatric drugs. Acta Psychiatric Scandinavica, June 2, 2022. https://doi.org/10.1111/acps.13459

Hoge EA, Bui E, Mete M, Dutton MA, Baker AW, Simon NM. (2022): Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical Trial. JAMA Psychiatry. 2023;80(1):13–21. doi:10.1001/jamapsychiatry.2022.3679

Horowitz, M.A., Framer, A., Hengartner, M.P. et al.(2022): Estimating Risk of Antidepressant Withdrawal from a Review of Published Data. CNS Drugs 37, 143–157 (2023). https://doi.org/10.1007/s40263-022-00960-y

Horowitz, M. A. & Taylor, D. (2022): Distinguishing relapse from antidepressant withdrawal: clinical practice and antidepressant discontinuation studies. BJPsych Advances. DOI: 10.1192/bja.2021.62

Horowitz, M., & Wilcock, M. (2022): Newer generation antidepressants and withdrawal effects: reconsidering the role of antidepressants and helping patients to stop. Drug and Therapeutics https://doi.org/10.1136/dtb.2020.000080

Liran C. Peleg, David Rabinovitch, Yaakov Lavie, Deya M. Rabbie, Itai Horowitz, Eyal Fruchter, Ilan Gruenwald, (2022): Post-SSRI Sexual Dysfunction (PSSD): Biological Plausibility, Symptoms, Diagnosis, and Presumed Risk Factors, Sexual Medicine Reviews, Volume 10, Issue 1, January 2022, Pages 91–98, https://doi.org/10.1016/j.sxmr.2021.07.001

Moncrieff, J., Cooper, R.E., Stockmann, T. et al.(2022): The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry 28, 3243–3256 (2023). https://doi.org/10.1038/s41380-022-01661-0

Moore TJ, Alami A, Alexander GC, Mattison DR. (2022): Safety and effectiveness of NMDA receptor antagonists for depression: A multidisciplinary review. Pharmacotherapy. 2022 Jul;42(7):567-579. doi: 10.1002/phar.2707. Epub 2022 Jun 26.

Nabi Z, Stansfeld J, Plöderl M, Wood L, Moncrieff J.: Effects of lithium on suicide and suicidal behaviour: a systematic review and meta-analysis of randomised trials. Epidemiology and Psychiatric Sciences. 2022;31:e65. doi:10.1017/S204579602200049X

Ormel Johan, Hollon Steven D., Kessler Ronald C., Cuijpers Pim, Monroe Scott M.(2022):
More treatment but no less depression: The treatment-prevalence paradox,
Clinical Psychology Review, Volume 91, 2022, https://doi.org/10.1016/j.cpr.2021.102111

Peleg, L. C., Rabinovitch, D., Lavie, Y., Rabbie, D. M., Horowitz, I., Fruchter, E., & Gruenwald, I. :(2022). Post-SSRI sexual dysfunction (PSSD): Biological plausibility, symptoms, diagnosis, and presumed risk factors. Sex Med Rev, 10, 91-98. https://doi.org/10.1016/j.sxmr.2021.07.001

Quilichini Jean-Baptiste, Revet Alexis, Garcia Philippe, Bouquié Régis, Hamard Jacques, Yrondi Antoine, Montastruc François (2022): Comparative effects of 15 antidepressants on the risk of withdrawal syndrome: A real-world study using the WHO pharmacovigilance database, Journal of Affective Disorders, Volume 297, 2022, Pages 189-193, ISSN 0165-0327,
https://doi.org/10.1016/j.jad.2021.10.041.

Read, John, (2022):The experiences of 585 people when they tried to withdraw from antipsychotic drugs, Addictive Behaviors Reports, Volume 15, 2022,100421, ISSN 2352-8532,
https://doi.org/10.1016/j.abrep.2022.100421.

Reid Finlayson AJ, Macoubrie J, Huff C, Foster DE, Martin PR. (2022): Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey. Therapeutic Advances in Psychopharmacology. 2022;12. https://doi.org/10.1177/20451253221082386

Schneider Michael, Grohmann Renate, Heinze Martin, Greiner Timo (2022): Ausgeprägte Gewichtszunahmen stationärer psychiatrischer Patienten unter Psychopharmaka: Daten aus dem AMSP-Projekt 2001–2016; Arzneiverordnung in der Praxis; Ausgabe 1/2022 https://www.akdae.de/arzneimitteltherap ... 2b4822783f

Sørensen A, Juhl Jørgensen K, Munkholm K. (2022): Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review. Therapeutic Advances in Psychopharmacology. 2022;12. https://doi.org/10.1177/20451253211067656

Sørensen, A., Ruhé, H.G. & Munkholm, K. (2022): The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review. Mol Psychiatry 27, 192–201 (2022). https://doi.org/10.1038/s41380-021-01285-w

Stone M B, Yaseen Z S, Miller B J, Richardville K, Kalaria S N, Kirsch I et al.( 2022) : Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: individual participant data analysis BMJ 2022; 378 :e067606 doi:10.1136/bmj-2021-067606

Tiihonen, J., Tanskanen, A., Bell, J. S., Dawson, J. L., Kataja, V., & Taipale, H. (2022): Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland. Lancet Psychiatry, 9, 353–62. https://doi.org/10.1016/S2215-0366(22)00044-X

Turner EH, Cipriani A, Furukawa TA, Salanti G, de Vries YA (2022): Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials. PLOS Medicine 19(1): e1003886 https://doi.org/10.1371/journal.pmed.1003886

[Team PsyAb]

2021

Breedvelt, J. J. F., Warren, F. C., Segal, Z., Kuyken, W., & Bockting, C. L. (2021): Continuation of antidepressants vs. sequential psychological interventions to prevent relapse in depression: An individual participant data meta-analysis. JAMA Psychiatry. Published online May 19, 2021. doi:10.1001/jamapsychiatry.2021.0823

Brown, M. Lewis, S. (2021): The Patient Voice: Antidepressant Withdrawal, Medically Unexplained Symptoms, and Functional Neurological Disorders. Journal of Critical Psychology, Counselling, and Psychotherapy, 20 (4), 14-20. https://www.researchgate.net/publicatio ... BrownLewis

Framer, A. (2021): What I have learned from helping thousands of people taper off antidepressants and other psychotropic medications. Therapeutic Advances in Psychopharmacology, 11, 2045125321991274. https://doi.org/10.1177/2045125321991274

Harrow M, Jobe TH, Tong L. (2021): Twenty-year effects of antipsychotics in schizophrenia and affective psychotic disorders. Psychological Medicine. 2022;52(13):2681-2691. https://doi.org/10.1017/s0033291720004778

Healy, D, Mangin, D, Lochhead, J (2021): Development and persistence of
patient-reported visual problems associated with serotonin reuptake inhibiting
antidepressants, International Journal of Risk & Safety in Medicine 33 (2022) 37–47 37 DOI 10.3233/JRS-210018 IOS Press https://rxisk.org/wp-content/uploads/20 ... 210018.pdf

Hengartner MP, Amendola S, Kaminski JA, et al (2021): Suicide risk with selective serotonin reuptake inhibitors and other new-generation antidepressants in adults: a systematic review and meta-analysis of observational studies. J Epidemiol Community Health 2021;75:523-530. https://doi.org/10.1136/jech-2020-214611

Hengartner, M. P., & Plöderl, M. (2021): Prophylactic effects or withdrawal reactions? An analysis of time-to-event data from antidepressant relapse prevention trials submitted to the FDA. Ther Adv Psychopharmacol, 11, 1–12. DOI: 10.1177/20451253211032051

Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021): A method for tapering antipsychotic treatment that may minimize the risk of relapse. Schizophrenia Bulletin, 47(4), 1116–1129. https://doi.org/10.1093/schbul/sbab017

Horowitz MA, & Taylor D. (2021): How to reduce and stop psychiatric medication. European Neuropsychopharmacology, 55, 4-7. https://doi.org/10.1016/j.euroneuro.2021.10.001

Horowitz, M., & Wilcock, M. (2021): Newer generation antidepressants and withdrawal effects: Reconsidering the role of antidepressants and helping patients to stop. Drug and Therapeutics Bulletin. https://doi.org/10.1136/dtb.2020.000080

Lincoln, T.M, Sommer, D., Könemund M., Schlier, B.(2021): A rating scale to inform successful discontinuation of antipsychotics and antidepressants, Psychiatry Research,
Volume 298, 2021,113768, ISSN 0165-1781, https://doi.org/10.1016/j.psychres.2021.113768.

Lewis S. (2021): Four research papers I wish my GP had read before prescribing antidepressants. British Journal of General Practice 2021; 71 (708): 316-317. https://doi.org/10.3399/bjgp21X716321

Lynch, T., Ryan, C., & Cadogan, C. (2021): ‘I just thought that it was such an impossible thing’: A qualitative study of barriers and facilitators to discontinuing long‐term use of benzodiazepine receptor agonists using the Theoretical Domains Framework. Health Expectations. https://doi.org/10.1111/hex.13392

Massabki I, Abi-Jaoude E.(2021): Selective serotonin reuptake inhibitor ‘discontinuation syndrome’ or withdrawal. The British Journal of Psychiatry. 2021;218(3):168-171. https://doi.org/10.1192/bjp.2019.269

Paulzen,M., Schreckenbach,T., Kirchner, M. (2021): Absetzen von Psychopharmaka - Antidepressiva und Antipsychotika. Psychopharmakotherapie 2021; 28(04):155-167
https://www.ppt-online.de/heftarchiv/20 ... otika.html

Van Leeuwen E, van Driel ML, Horowitz MA, Kendrick T, Donald M, De Sutter AIM, Robertson L, Christiaens T. (2021): Ansätze für Abbruch versus Fortsetzung des Langzeit-Antidepressivums für depressive und Angststörungen bei Erwachsenen. Cochrane Datenbank für Systematische Bewertungen 2021, Ausgabe 4. Art. Nr.: CD013495 https://doi.org/10.1002/14651858.CD013495.pub2

White, E., Read, J., & Julo, S. (2021): Facebook groups’ role in the management and raising of awareness of antidepressant withdrawal: Is social media filling the void left by health services? Therapeutic Advances in Psychopharmacology, 11, 1-18. https://doi.org/10.1177/2045125320981174


2020

Brandt, L., Bschor, T., Henssler, J., Müller, M., Hasan, A., Heinz, A., & Gutwionski, S. (2020): Antipsychotic withdrawal symptoms: A systematic review and meta-analysis. Frontiers in Psychiatry, 11, 569912. https://doi.org/10.1016/s2215-0366(22)00014-1

Cosci F, Chouinard G. (2020) Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications. Psychother Psychosom. 2020;89(5):283-306. Epub 2020 Apr 7. PMID: 32259826. doi: 10.1159/000506868.

Fava, G. A. (2020): May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance. Therapeutic Advances in Psychopharmacology, 10, https://doi.org/10.1177/2045125320970325

Groot PC, & van Os J. (2020): Outcome of antidepressant drug discontinuation with tapering strips after 1–5 years. Therapeutic Advances in Psychopharmacology, 10, 1–8. doi: 10.1177/2045125320954609

Guy A, Brown M, Lewis S, Horowitz M. (2020): The 'patient voice': patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition. Ther Adv Psychopharmacol. 2020 Nov 9;10:2045125320967183. PMID: 33224468; PMCID: PMC7659022. doi: 10.1177/2045125320967183.

Hengartner MP. (2020): How effective are antidepressants for depression over the long term? A critical review of relapse prevention trials and the issue of withdrawal confounding. Therapeutic Advances in Psychopharmacology. 2020;10. https://doi.org/10.1177/2045125320921694

Hengartner, MP., Jakobsen, J. C., Sørensen, A., & Plöderl, M. (2020). Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials. PloS one, 15(2), https://doi.org/10.1371/journal.pone.0229381

Hengartner MP, Schulthess L, Sorensen A, & Framer A. (2020): Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum. Ther Adv Psychopharmacol, 10, 1-13. https://doi.org/10.1177/2045125320980573

Horowitz, MA, Murray RM, & Taylor D. (2020): Tapering antipsychotic treatment. JAMA Psychiatry. Published online, August 5, 2020. DOI:10.1001/jamapsychiatry.2020.2166

Kendrick, T. (2020): Strategies to reduce the use of antidepressants. British Journal of Clinical Pharmacology. DOI: 10.1111/bcp.14475

Moncrieff J, Gupta S, Horowitz MA (2020):. Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorder. Therapeutic Advances in Psychopharmacology. 2020;10. https://doi.org/10.1177/2045125320937910

Read, J. (2020): How common and severe are six withdrawal effects from, and addiction to, antidepressants? The experiences of a large international sample of patients, Addictive Behaviors, Volume 102, 2020,106157, ISSN 0306-4603,
https://doi.org/10.1016/j.addbeh.2019.106157.

Tondo L, Baldessarini RJ. (2020): Discontinuing psychotropic drug treatment. BJPsych Open. 2020;6(2):e24. https://doi.org/10.1192/bjo.2020.6

Weir, K. (2020): How hard is it to stop antidepressants? Monitor on Psychology, 51(3). https://www.apa.org/monitor/2020/04/sto ... epressants

Zhong, X., Harris, G., Smirnova, L., Zufferey, V. 3, Sá, R., Russo, F. B., . . . & Pamies, D. (2020): Antidepressant paroxetine exerts developmental neurotoxicity in an iPSC-derived 3D human brain model. Front. Cell. Neurosci, 14(25) https://doi.org/10.3389/fncel.2020.00025


2019

Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox (2029): Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study. JAMA Intern Med. 2019;179(8):1084–1093. doi:10.1001/jamainternmed.2019.0677
https://jamanetwork.com/journals/jamain ... le/2736353

Cohen D, Recalt A.: Discontinuing Psychotropic Drugs from Participants in Randomized Controlled Trials: A Systematic Review. Psychother Psychosom. 2019;88(2):96-104. Epub 2019 Mar 28. PMID: 30923288. https://doi.org/10.1159/000496733

Cooper, R.E., Hanratty, É., Morant, N., & Moncrieff, J. (2019): Mental health professionals’ views and experiences of antipsychotic reduction and discontinuation. PLoS ONE, 14(6): e0218711. https://doi.org/10.1371/journal.pone.0218711

Danborg PB, Valdersdorf M, Gøtzsche PC (2019): Long-term harms from previous use of selective serotonin reuptake inhibitors: A systematic review. International Journal of Risk & Safety in Medicine. 2019;30(2):59-71. https://doi.org/10.3233/JRS-180046

Davies, J., Read, J (2019): A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based?,
Addictive Behaviors, Volume 97, 2019, Pages 111-121, ISSN 0306-4603,
https://doi.org/10.1016/j.addbeh.2018.08.027.

Fava, G. A., & Cosci, F. (2019): Addressing clinical challenges of antidepressant discontinuation. American Journal of Psychiatry, 176(6), 487-488. https://doi.org/10.1176/appi.ajp.2019.18121419

Fava GA, Cosci F. (2019): Understanding and managing withdrawal syndromes after discontinuation of antidepressant drugs. J Clin Psychiatry. 2019;80(6):19com12794.
https://doi.org/10.4088/JCP.19com12794

Fornaro M, Anastasia A, et al. (2019): The emergence of loss of efficacy during antidepressant drug treatment for major depressive disorder: an integrative review of evidence, mechanisms, and clinical implications. Pharmacol Res 139:494–502, ISSN 1043-6618, https://doi.org/10.1016/j.phrs.2018.10.025.

Hengartner MP, Davies J, Read J.(2019): Antidepressant withdrawal – the tide is finally turning. Epidemiology and Psychiatric Sciences. 2020;29:e52. https://doi.org/10.1017/S2045796019000465

Horowitz, Mark Abie, Taylor, David (2019): Tapering of SSRI treatment to mitigate withdrawal symptoms, The Lancet Psychiatry, Volume 6, Issue 6, 538 - 546, DOI:https://doi.org/10.1016/S2215-0366(19)30032-X

Iacobucci G. (2019): NICE updates antidepressant guidelines to reflect severity and length of withdrawal symptoms BMJ 2019; 367 :l6103 https://doi.org/10.1136/bmj.l6103

Kaufmann, Markus, Lehmann, Peter (2019): Überfällige ärztliche Hilfen beim Absetzen von Antidepressiva und Neuroleptika, NeuroTransmitter, 30. Jg. (2019), Nr. 12, S. 18-22
https://www.researchgate.net/publicatio ... uroleptika

Kirsch I. (2019): Placebo Effect in the Treatment of Depression and Anxiety. Front Psychiatry. 2019 Jun 13;10:407. doi: 10.3389/fpsyt.2019.00407. PMID: 31249537; PMCID: PMC6584108.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6584108/

Lerner Alicja, Klein Michael (2019): Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development, Brain Communications, Volume 1, Issue 1, 2019, fcz025, https://doi.org/10.1093/braincomms/fcz025

Maund, E., Stuart, B., Moore, M., Dowrick, C., Geraghty, A.W.A., Dawson, S., & Kendrick, T. :(2019). Managing antidepressant discontinuation: A systematic review. Annals of Family Medicine 17(1). DOI: https://doi.org/10.1370/afm.2336

Read J, Williams J.(2019): Positive and Negative Effects of Antipsychotic Medication: An International Online Survey of 832 Recipients. Curr Drug Saf. 2019;14(3):173-181. PMID: 30827259; PMCID: PMC6864560. https://doi.org/10.2174/1574886314666190301152734

[Team PsyAb]

2018

Aydemir, E., Aslan, E., & Yazici, M. (2018): SSRI Induced Apathy Syndrome. Psychiatry and Behavioral Sciences, 8(2), 63. PDF https://doi.org/10.5455/PBS.20180115111230

Baier, A., Bschor,T. (2018): Warum Antidepressiva-Studien scheitern: Zunehmender Placeboeffekt oder abnehmende Wirksamkeit? Arzneimittelkommission der deutschen Ärzteschaft, Arzneiverordnung in der Praxis, Ausgabe 1/2019
https://www.akdae.de/arzneimitteltherap ... 5845330854

Davies, J., Pauli, R., Montagu, L. (2018): Antidepressant Withdrawal: a Survey of Patients’ Experience by the All-Party Parliamentary Group for Prescribed Drug Dependence (September 2018) http://prescribeddrug.org/wp-content/up ... iences.pdf

Davies, J., Read, J. (2018): A systematic review into the incidence, severity, and duration of antidepressant withdrawal effects: Are guidelines evidence-based?. Addictive Behaviors. https://doi.org/10.1016/j.addbeh.2018.08.027

Everitt H, Baldwin DS, Stuart B, Lipinska G, Mayers A, Malizia AL, Manson CCF, Wilson S. (2018): Antidepressants for insomnia in adults. Cochrane Database of Systematic Reviews 2018, Issue 5. Art. No.: CD010753. https://doi.org/10.1002/14651858.CD010753.pub2

Fava, G. & Belaise, C. (2018): Discontinuing antidepressant drugs: Lesson from a failed trial and extensive clinical experience. Psychotherapy and Psychosomatics, 87, 257-267.
https://doi.org/10.1159/000492693

Fava, G., Benasi, G., Lucente, M., Offidani, E., Cosci, F., Guidi, J. (2018): Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review. Psychother Psychosom 7 August 2018; 87 (4): 195–203. https://doi.org/10.1159/000491524

Healy D, Le Noury J, Mangin D. (2018): Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases. International Journal of Risk & Safety in Medicine. 2018;29(3-4):125-134. https://doi.org/10.3233/JRS-180744

Larsen-Barr, M., Seymour, F., Read, J., & Gibson, K. (2018): Attempting to discontinue antipsychotic medication: withdrawal methods, relapse, and success. Psychiatry research. https://doi.org/10.1016/j.psychres.2018.10.001

Moncrieff J.(2018): Against the stream: Antidepressants are not antidepressants – an alternative approach to drug action and implications for the use of antidepressants. BJPsych Bulletin. 2018;42(1):42-44. doi:10.1192/bjb.2017.11 https://www.cambridge.org/core/journals ... 38B2FAE43E

Munkholm K, Paludan-Müller AS, Boesen K (2018): Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis BMJ Open 2019;9:e024886. doi: 10.1136 bmjopen-2018-024886
https://bmjopen.bmj.com/content/9/6/e024886

Perry T, editor.(2018): Therapeutics Letter. Vancouver (BC): Therapeutics Initiative; 1994-. Letter 112, Antidepressant Withdrawal Syndrome. 2018 Jun. Available from: https://www.ncbi.nlm.nih.gov/books/NBK598502/

Read, J., Gee, A., Diggle, J., & Butler, H. (2018): Staying on, and coming off, antidepressants: The experiences of 752 UK adults. Addictive Behaviors. https://doi.org/10.1016/j.addbeh.2018.08.021

Read, J., Williams, J. (2018): Adverse Effects of Antidepressants Reported by a Large International Cohort: Emotional Blunting, Suicidality, and Withdrawal Effects, Bentham Science Volume 13, Issue 3, 2018, Page: [176 - 186]
http://dx.doi.org/10.2174/1574886313666180605095130

Stockmann, T., Odegbaro, D., Timimi, S., & Moncrieff, J. (2018): SSRI and SNRI withdrawal symptoms reported on an internet forum. International Journal of Risk & Safety in Medicine, 29(3-4), https://doi.org/10.1080/17522439.2018.1469163

Welsch P, Bernardy K, Derry S, Moore RA, Häuser W. (2018): Mirtazapine for fibromyalgia in adults. Cochrane Database of Systematic Reviews 2018, Issue 8. Art. No.: CD012708. https://doi.org/10.1002/14651858.CD012708.pub2


2017

Chouinard, G., Samaha, A., Chouinard, V., Peretti, C., Kanahara, N., Takase, M., & Iyo, M. (2017): Antipsychotic-induced dopamine supersensitivity psychosis: Pharmacology, criteria, and therapy. Psychotherapy and Psychosomatics, 86, 189–219. https://doi.org/10.1159/000477313

Crowe, S.F., Stranks, E.K. (2017): The Residual Medium and Long-term Cognitive Effects of Benzodiazepine Use: An Updated Meta-analysis, Archives of Clinical Neuropsychology, Volume 33, Issue 7, November 2018, Pages 901–911, https://doi.org/10.1093/arclin/acx120

Eveleigh, R., Muskens, E., Lucassen, P., Verhaak, P., Spijker, J., van Weel, C., … & Speckens, A. (2017): Withdrawal of unnecessary antidepressant medication: a randomised controlled trial in primary care. BJGP Open, BJGP-2017. DOI: https://doi.org/10.3399/bjgpopen17X101265

Goodwin, G. M., Price, J., De Bodinat, C., Laredo, J. (2017): Emotional blunting with antidepressant treatments: A survey among depressed patients. Journal of Affective Disorders, 221, 31–35. https://doi.org/10.1016/j.jad.2017.05.048

Maund, E., Guski, L.S., Gøtzsche, P. C. (2017): Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports. CMAJ Feb 2017, 189 (5) E194-E203; https://doi.org/10.1503/cmaj.151104

Read, J., Gee, A., Diggle, J., & Butler, H. (2017): The interpersonal adverse effects reported by 1,008 users of antidepressants; and the incremental impact of polypharmacy. Psychiatry Research
https://doi.org/10.1016/j.psychres.2017.07.003

Ostrow, L., Jessell, L., Hurd, M., Darrow, S. M., & Cohen, D. (2017). Discontinuing psychiatric medications: A survey of long-term users. Psychiatric Services, 68(7).
https://doi.org/10.1176/appi.ps.201700070

Yin J, Barr AM, Ramos-Miguel A, Procyshyn RM.:(2017) Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review. Curr Neuropharmacol. 2017;15(1):174-183. PMID: 27264948; PMCID: PMC5327459. https://doi.org/10.2174/1570159x14666160606093602 https://pubmed.ncbi.nlm.nih.gov/27264948/


2016

Akoudad,S., Aarts, N., Noordam, R., Ikram, M. A., Tiemeier, H., Hofman, A., Stricker, B. H., Vernooij, M. W., Visser, L. E.
(2016): Antidepressant Use Is Associated With an Increased Risk of Developing Microbleeds. Stroke 47: 251-254
doi: 10.1161/STROKEAHA.115.011574 http://stroke.ahajournals.org/content/4 ... fc612c61ac

Bielefeldt AØ, Danborg PB, Gøtzsche PC. (2016): Precursors to suicidality and violence on antidepressants: systematic review of trials in adult healthy volunteers. Journal of the Royal Society of Medicine. 2016;109(10):381-392. https://doi.org/10.1177/0141076816666805

Breggin, PR. (2016): Rational Principles of Psychopharmacology for Therapists, Healthcare Providers and Clients. J Contemp Psychother 46:1–13. https://link.springer.com/article/10.10 ... 015-9307-2

Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016): The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: A critical review of the literature. Psychotherapy and Psychosomatics, 85(5), 270-288 https://doi.org/10.1159/000447034

Kirsch,I. (2016): Der Placeboeffekt in der antidepressiven Behandlung. Verhaltenstherapie 1 February 2016; 26 (1): 55–61. https://doi.org/10.1159/000443542

Li M. (2016): Antipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanisms. Journal of Psychopharmacology. 2016;30(8):749-770. https://doi.org/10.1177/0269881116654697

Lucire, Y. (2016): Pharmacological Iatrogenesis: Substance/Medication-Induced Disorders That Masquerade as Mental Illness. Epidemiology (sunnyvale) 6:1 https://www.researchgate.net/publicatio ... al_Illness

Moraros, J., Nwankwo, C., Patten, S. B., & Mousseau, D. D. (2016): The association of antidepressant drug usage with cognitive impairment or dementia, including Alzheimer disease: A systematic review and meta-analysis. Depression and Anxiety, 34, 217–226.
https://doi.org/10.1002/da.22584

Murray RM, Quattrone D, Natesan S, et al.(2016): Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? British Journal of Psychiatry. 2016;209(5):361-365. https://doi.org/10.1192/bjp.bp.116.182683

Satoshi Ueda, Takeshi Sakayori, Ataru Omori, Hajime Fukuta, Takashi Kobayashi, Kousuke Ishizaka, Tomoyuki Saijo, Yoshiro Okubo (2016): Neuroleptic-induced deficit syndrome in bipolar disorder with psychosis Neuropsychiatr Dis Treat. 2016; 12: 265–268. doi: 10.2147/NDT.S99577
PMCID: PMC4745952 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745952/

Sharma, T., Schow Guski, L., Freund, N., Gøtzsche, P. C. (2016): Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports British Medical Journal 352:i65 doi: http://dx.doi.org/10.1136/bmj.i65 http://www.bmj.com/content/352/bmj.i65.full.pdf+html

Uher, R., Pavlova, B. (2016): Long-term effects of depression treatment. The Lancet Psychiatry 3 (2): 95 - 96 http://dx.doi.org/10.1016/S2215-0366(15)00578-7 http://www.thelancet.com/pdfs/journals/ ... 0578-7.pdf


2015

Amerio, A., Gálvez, J. F. Odone, A., Dalley, S. A., Ghaemi, S. N. (2015): Carcinogenicity of psychotropic drugs: A systematic review of US Food and Drug Administration–required preclinical in vivo studies. Australian & New Zealand Journal of Psychiatry 49(8): 686–696 DOI: 10.1177/0004867415582231 http://anp.sagepub.com/content/49/8/686.full.pdf+html

Andrews, P. W., Bharwania, A., Leea, K. R., Fox, M., Anderson Thomson, J., Jr. (2015): Is serotonin an upper or a downer? The evolution of the serotonergic system and its role in depression and the antidepressant response. Neuroscience & Biobehavioral Reviews 51: 164–188
doi:10.1016/j.neubiorev.2015.01.018 http://www.sciencedirect.com/science/ar ... 3415000287

Chouinard, G., Chouinard, V. (2015): New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal. Psychother Psychosom 84:63-71. DOI:10.1159/000371865 http://www.karger.com/Article/Pdf/371865

Cressman, A. M., Macdonald, E. M., Huang, A., Gomes, T., Paterson, M., Kurdyak, P. A., Mamdani, M. M., Juurlink, D. N.
(2015): Prescription Stimulant Use and Hospitalization for Psychosis or Mania: A Population-Based Study. Journal of Clinical Psychopharmacology 35(6): 667–671 doi: 10.1097/JCP.0000000000000406 http://journals.lww.com/psychopharmacol ... for.8.aspx

Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. (2015): Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review. Psychother Psychosom. 2015;84(2):72-81. Epub 2015 Feb 21. PMID: 25721705. https://doi.org/10.1159/000370338

Fava, G.A., Guidi, J., Rafanelli, C., Sonino, N. (2015): The Clinical Inadequacy of Evidence-Based Medicine and the Need for a Conceptual Framework Based on Clinical Judgment. Psychother Psychosom 84:1-3 DOI:10.1159/000366041 http://www.karger.com/Article/Pdf/366041

Hawthorne JM, Caley CF.(2015): Extrapyramidal Reactions Associated With Serotonergic Antidepressants. Annals of Pharmacotherapy. 2015;49(10):1136-1152 https://doi.org/10.1177/1060028015594812

Healy D. (2015): Serotonin and depression BMJ 2015; 350 :h1771 https://doi.org/10.1136/bmj.h1771

Khan, A. and Brown, W.A. (2015), Antidepressants versus placebo in major depression: an overview. World Psychiatry, 14: 294-300. https://doi.org/10.1002/wps.20241

Lacasse, J. R., Leo, J. (2015): Antidepressants and the Chemical Imbalance Theory of Depression: A Reflection and Update on the Discourse. The Behavior Therapist 38(7): 206-213. https://www.researchgate.net/publicatio ... _Discourse

Le Noury, J., Nardo, J. M., Healy, D., Jureidini, J., Raven, M., Tufanaru, C., Abi-Jaoude, E. (2015): Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence BMJ 2015;351:h4320 doi:10.1136/bmj.h4320 http://study329.org/wp-content/uploads/ ... -Final.pdf

Moncrieff, J. (2015): Antidepressants: misnamed and misrepresented. World Psychiatry 14(3): 302–303 DOI: 10.1002/wps.20243 http://onlinelibrary.wiley.com/doi/10.1 ... 20243/epdf

Takayanagi, Y., Spira, A.P., Bienvenu, O.J., Hock, R.S., Carras, M.C., Eaton, W.W., Mojtabai, R. (2015): Antidepressant use and lifetime history of mental disorders in a community sample: results from the Baltimore Epidemiologic Catchment Area Study. J Clin Psychiatry 76(1):40-4
doi: 10.4088/JCP.13m08824 http://www.ncbi.nlm.nih.gov/pmc/article ... 695626.pdf

[Team PsyAb]

2014

Aderhold, V. (2014): "Neuroleptika minimal - warum und wie" (PDF)
https://www.dgsp-ev.de/images/Themen%20 ... Januar.pdf

Kirsch I.(2014): Antidepressants and the Placebo Effect. Z Psychol. 2014;222(3):128-134. doi: 10.1027/2151-2604/a000176. PMID: 25279271; PMCID: PMC4172306.
https://pmc.ncbi.nlm.nih.gov/articles/PMC4172306/

Maund, E., Tendal, B.,Hróbjartsson, A.,Jørgensen, K. J., Lundh, A., Schroll, J., Gøtzsche, P. C. (2014): Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications BMJ 2014; 348 doi: http://dx.doi.org/10.1136/bmj.g3510 http://www.bmj.com/content/bmj/348/bmj.g3510.full.pdf

Miller M, Swanson SA, Azrael D, Pate V, Stürmer T. (2014): Antidepressant Dose, Age, and the Risk of Deliberate Self-harm. JAMA Intern Med. 2014;174(6):899–909. doi:10.1001/jamainternmed.2014.1053
https://jamanetwork.com/journals/jamain ... le/1863925

Moncrieff, J. (2014): The Nature of Mental Disorder: Disease, Distress, or Personal Tendency? Philosophy, Psychiatry, & Psychology 21;3: 257-260 http://muse.jhu.edu/journals/philosophy ... rieff.html

Read, J., Cartwright, C., Gibson, K. (2014): Adverse emotional and interpersonal effects reported by 1829 New Zealanders while taking antidepressants. Psychiatry Res. 30;216(1):67-73 doi: 10.1016/j.psychres.2014.01.042 http://www.ncbi.nlm.nih.gov/pubmed/24534123

Salomon, C., Hamilton, B. and Elsom, S. (2014): Antipsychotic discontinuation. J Psychiatr Ment Health Nurs, 21: 917-923. https://doi.org/10.1111/jpm.12178

Thomas, . H., Martin, R. M., Potokar, J., Pirmohamed, M., Gunnell, D. (2014): Reporting of drug induced depression and fatal and non-fatal suicidal behaviour in the UK from 1998 to 2011. BMC Pharmacol Toxicol.15: 54. doi: 10.1186/2050-6511-15-54 PMCID: PMC4184159 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184159/


2013

Nielsen, M., Hansen, E.H., Gøtzsche P.C.(2013): Dependence and withdrawal reactions to benzodiazepines and selective serotonin reuptake inhibitors. How did the health authorities react? GInt J Risk Saf Med 25(3):155-68. doi: 10.3233/JRS-130594. http://www.ncbi.nlm.nih.gov/pubmed/24047687

Prousky, J. E. (2013): Tapering Off Psychotropic Drugs: Using Patient Cases to Understand Reasons for Success and Failure. Journal of Orthomolecular Medicine 28:4 159-174 https://www.academia.edu/83870637/Taper ... nd_Failure

Renoir, T. (2013): Selective Serotonin Reuptake Inhibitor Antidepressant Treatment Discontinuation Syndrome: A Review of the Clinical Evidence and the Possible Mechanisms Involved. Front Pharmacol 4: 45 doi: 10.3389/fphar.2013.00045 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627130/

Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, et al. (2013): Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes. PLOS Medicine 10(3): e1001403. https://doi.org/10.1371/journal.pmed.1001403

Wang Q, Cheung C, Deng W, Li M, Huang C, Ma X, Wang Y, Jiang L, Sham PC, Collier DA, Gong Q, Chua SE, McAlonan GM, Li T. (2013): White-matter microstructure in previously drug-naive patients with schizophrenia after 6 weeks of treatment. Psychol Med. 2013 Nov;43(11):2301-9. Epub 2013 Feb 27. PMID: 23442742. DOI: 10.1017/S0033291713000238 https://pubmed.ncbi.nlm.nih.gov/23442742/


2012

Andrews Paul W., Thomson J. Anderson , Amstadter Ananda , Neale Michael C. (2012):
Primum Non Nocere: An Evolutionary Analysis of Whether Antidepressants Do More Harm than Good, Frontiers in Psychology, Volume 3 - 2012 | https://doi.org/10.3389/fpsyg.2012.00117

Antonuccio,D., Healy, D, (2012): Relabeling the Medications We Call Antidepressants. Scientifica, vol. 2012, Article ID 965908, 6 pages. doi:10.6064/2012/965908 https://onlinelibrary.wiley.com/doi/pdf ... 012/965908

Belaise, C., Gatti, A., Chouinard, V. A., & Chouinard, G. (2012): Patient online report of selective serotonin reuptake inhibitor-induced persistent postwithdrawal anxiety and mood disorders. Psychotherapy and psychosomatics, 81(6), 386-388. https://doi.org/10.1159/000341178

Breggin, P. R. (2012): Psychiatric drug-induced Chronic Brain Impairment (CBI): Implications for longterm treatment with psychiatric medication International Journal of Risk & Safety in Medicine 23: 193-200. https://breggin.com/admin/fm/source/690 ... irment.pdf

Clewes J. (2012): A case report of onset of tinnitus following discontinuation of antidepressant and a review of the literature. Prim Care Companion CNS Disord. 2012;14(1):PCC.11br01218. Epub 2012 Feb 16. PMID: 22690352; PMCID: PMC3357564.
https://doi.org/10.4088/PCC.11br01218

Lehmann, Peter (2012): Probleme beim Absetzen von Neuroleptika als Folge von Rezeptorenveränderungen und Toleranzbildung. Internet-Veröffentlichung vom Juli 2012
https://antipsychiatrieverlag.de/artike ... ez-ver.htm

Nielsen, M., Hansen, E.H., Gøtzsche, P.C. (2012): What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. Addiction 107(5):900-8. doi: 10.1111/j.1360-0443.2011.03686.x. http://www.ncbi.nlm.nih.gov/pubmed/21992148


2011

Andrews, P. W., Kornstein, S., G., Halberstadt, L. J., Gardner, C. O., Neale, M. C.(2011): Blue again: perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression Front Psychol 2: 159. doi: 10.3389/fpsyg.2011.00159 http://www.ncbi.nlm.nih.gov/pmc/article ... -00159.pdf

Andrews, P.W., Thomson, J.A., Amstadter, A., Neale, M.C. (2011): Primum non nocere: an evolutionary analysis of whether antidepressants do more harm than good Front Psychol. 24;3:117. doi: 10.3389/fpsyg.2012.00117 http://www.ncbi.nlm.nih.gov/pmc/article ... -00117.pdf

El-Mallakh, R. S., Gao, Y., Jeannie Roberts, R. (2011): Tardive dysphoria: the role of long term antidepressant use in-inducing chronic depression Med Hypotheses 76(6):769-73 doi: 10.1016/j.mehy.2011.01.020 http://www.ncbi.nlm.nih.gov/pubmed/21459521

Fava, G.A., Offidani E. (2011): The mechanisms of tolerance in antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 5;35(7):1593-602. doi: 10.1016/j.pnpbp.2010.07.026 http://www.ncbi.nlm.nih.gov/pubmed/20728491

Furukawa, T.A. (2011): Rapid discontinuation of antidepressants reduces time to recurrence of depression and panic
Evid Based Mental Health 14:13 https://mentalhealth.bmj.com/content/eb ... 3.full.pdf

Goldsmith, L., Moncrieff, J. (2011): The Psychoactive Effects of Antidepressants and their Association with Suicidality. Current Drug Safety Vol 6(2): 115-121(7)
https://joannamoncrieff.files.wordpress ... ds0311.pdf
https://pubmed.ncbi.nlm.nih.gov/21375477/

Katz G. (2011):Tachyphylaxis/tolerance to antidepressants in treatment of dysthymia: results of a retrospective naturalistic chart review study. Psychiatry Clin Neurosci. 2011 Aug;65(5):499-504. doi: 10.1111/j.1440-1819.2011.02231.x.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21851459 Volltext: https://onlinelibrary.wiley.com/doi/ful ... 11.02231.x

Middleton, H., Moncrief, J. (2011): 'They won't do any harm and might do some good': Time to think again on the use of antidepressants? British Journal of General Practice 61:47–49 DOI:10.3399/bjgp11X548983 http://www.ncbi.nlm.nih.gov/pmc/article ... 61-047.pdf

Nielsen M., Gøtzsche P. (2011): An analysis of psychotropic drug sales. Increasing sales of selective serotonin reuptake inhibitors are closely related to number of products Int J Risk Saf Med. 23(2):125-32. doi: 10.3233/JRS-2011-0526 http://www.ncbi.nlm.nih.gov/pubmed/21673422

Narayan, V., Haddad, P.M. (2011): Antidepressant discontinuation manic states: a critical review of the literature and suggested diagnostic criteria.
J Psychopharmacol. 25(3):306-13. http://www.ncbi.nlm.nih.gov/pubmed/20156925

van Donkelaar, E. L., Blokland, A., Ferrington, L., Kelly, P.A.T., Steinbusch, H.W.M., Prickaerts, J. (2011): Mechanism of acute tryptophan depletion: is it only serotonin? Molecular Psychiatry 16, 695–713 http://www.nature.com/mp/journal/v16/n7 ... 20119a.pdf

Whitaker, (2011): SSRIs, Now Antidepressant-Induced Chronic Depression Has a Name: Tardive Dysphoria, New research on why antidepressants may worsen long-term outcomes, Psychology Today https://www.psychologytoday.com/gb/blog ... -dysphoria


2010

Baldessarini, R.J., Tondo, L., Ghiani, C., Lepri, B. (2010): Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry 167(8):934-41. doi: 10.1176/appi.ajp.2010.09060880 http://ajp.psychiatryonline.org/doi/abs ... b%3Dpubmed

Chen PY, Lin PY, Tien SC, Chang YY, Lee Y. (2010): Duloxetine-related tardive dystonia and tardive dyskinesia: a case report. Gen Hosp Psychiatry. 2010 Nov-Dec;32(6):646.e9-646.e11. Epub 2010 Jun 3. PMID: 21112461. https://doi.org/10.1016/j.genhosppsych.2010.04.009

Howland, R.H. (2010): Potential adverse effects of discontinuing psychotropic drugs. Part 1: Adrenergic, cholinergic, and histamine drugs.J Psychosoc Nurs Ment Health Serv. 2010 Jun;48(6):11-4. http://www.mediafire.com/download/uuwnd ... nergic.pdf

Howland, R.H. (2010): Potential adverse effects of discontinuing psychotropic drugs. Part 2: antidepressant drugs. J Psychosoc Nurs Ment Health Serv. 2010 Jul;48(7):9-12. doi: 10.3928/02793695-20100527-98. http://www.mediafire.com/download/0572r ... ssants.pdf

Howland, R.H. (2010): Potential adverse effects of discontinuing psychotropic drugs. Part 3: Antipsychotic, dopaminergic, and mood-stabilizing drugs. J Psychosoc Nurs Ment Health Serv. 2010 Aug;48(8):11-4. http://www.mediafire.com/download/xsv6w ... chotic.pdf

Howland, R.H. (2010): Potential adverse effects of discontinuing psychotropic drugs. Part 4: Part 4: Benzodiazepine, Glutamate, Opioid, and Stimulant Drugs. J Psychosoc Nurs Ment Health Serv. 2010 Sep;48(9):11-4. doi: 10.3928/02793695-20100730-04. Epub 2010 Aug 23. http://www.mediafire.com/download/1akzt ... benzos.pdf

Sansone, R.A., Sansone, L.A., (2010): SSRI-Induced Indifference. Psychiatry (Edgemont) 7(10):14–18 http://www.ncbi.nlm.nih.gov/pmc/article ... _10_14.pdf

Smith, P. F., & Darlington, C. L. (2010): A possible explanation for dizziness following SSRI discontinuation. Acta Oto-Laryngologica, 130(9), 981–983. https://doi.org/10.3109/00016481003602082


2009

Price, J., Cole, V., & Goodwin, G. M. (2009): Emotional side-effects of selective serotonin reuptake inhibitors: Qualitative study. The British Journal of Psychiatry: The Journal of Mental Science, 195(3), 211–217. https://doi.org/10.1192/bjp.bp.108.051110

Weinmann, S., Read, J., & Aderhold, V. (2009): The influence of antipsychotics on mortality in schizophrenia: A systematic review. Schizophrenia Research, 113, 1–11. https://doi.org/10.1016/j.schres.2009.05.018


2008

Aderhold,V. (2008): "Zur Notwendigkeit und Möglichkeit minimaler Anwendung von Neuroleptika" (PDF)
https://www.dgsp-ev.de/images/Themen%20 ... en_6.0.pdf

Csoka AB, Bahrick A, Mehtonen OP. (2008): Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors. J Sex Med. 2008 Jan;5(1):227-33. Erratum in: J Sex Med. 2008 Dec;5(12):2977.. Csoka, A [corrected to Csoka, AB]. PMID: 18173768. https://doi.org/10.1111/j.1743-6109.2007.00630.x

Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT.(2008): Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008 Feb;5(2):e45. PMID: 18303940; PMCID: PMC2253608. doi: 10.1371/journal.pmed.0050045. https://doi.org/10.1371/journal.pmed.0050045

Moret C, Isaac M, Briley M.(2008): Review: Problems associated with long-term treatment with selective serotonin reuptake inhibitors. Journal of Psychopharmacology. 2009;23(8):967-974. https://doi.org/10.1177/0269881108093582

Rothschild AJ (2008): The Rothschild scale for antidepressant tachyphylaxis: reliability and validity. Compr Psychiatry Volume 49, Issue 5, 2008, Pages 508-513, ISSN 0010-440X, https://doi.org/10.1016/j.comppsych.2008.03.002


2007

Aderhold,V. (2007): Mortalität durch Neuroleptika, Soziale Psychiatrie (4/2007)
https://www.dgsp-ev.de/images/Themen%20 ... rhold_.pdf

Bockting, C.L.H., Doesschate, M.C. ten, Spijker, J., Spinhoven, P., Maarten W.J., Koeter, W.J., Schene A.H. (2007): Continuation and Maintenance Use of Antidepressants in Recurrent Depression. Psychother Psychosom 1 December 2007; 77 (1): 17–26. https://doi.org/10.1159/000110056


2006

Moncrieff, J. (2006): Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatrica Scandinavica, 114, 3–13. https://doi.org/10.1111/j.1600-0447.2006.00787.x

Moncrieff, J.(2006): Why is it so difficult to stop psychiatric drug treatment? It may be nothing to do with the original problem. Medical Hypotheses 67, 517-523 http://psychrights.org/Articles/Moncrie ... rugred.pdf

Moncrieff, J., Cohen, D. (2006): Do Antidepressants Cure or Create Abnormal Brain States? PLoS Med 3(7): e240 https://doi.org/10.1371/journal.pmed.0030240

Shelton, R.C. (2006): The nature of the discontinuation syndrome associated with antidepressant drugs. J Clin Psychiatry. 2006;67 Suppl 4:3-7. http://www.mediafire.com/download/1ax1a ... helton.pdf


2005

Solomon DA, Leon AC, Mueller TI et al: (2005) Tachyphylaxis in unipolar major depressive disorder. J Clin Psychiatry 2005;66(3):283-290
https://www.psychiatrist.com/jcp/tachyp ... -disorder/


2004

Breggin, P. R. (2004): Suicidality, violence and mania caused by selective serotonin reuptake inhibitor (SSRIs): A review and analysis. International Journal of Risk & Safety in Medicine 16:31–49 https://journals.sagepub.com/doi/abs/10 ... S-2004-292

Jahn, H., Schneider, T.(2024): Diabetes mellitus als Komplikation der Behandlung mit atypischen Neuroleptika. Nervenarzt 75, 442–450 (2004). https://doi.org/10.1007/s00115-003-1646-7

Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A.,Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., Houle, S. (2004): Serotonin Transporter Occupancy of Five Selective Serotonin Reuptake Inhibitors at Different Doses: An [11C]DASB Positron Emission Tomography Study Am J Psychiatry 161:826–835 https://psychiatryonline.org/doi/full/1 ... .161.5.826

2003
Fava, G. A. (2003): Can Long-Term Treatment With Antidepressant Drugs Worsen the Course of Depression? J Clin Psychiatry. 2003 Feb;64(2):123-133.. PMID: 12633120. https://doi.org/10.4088/jcp.v64n0204,
http://www.madinamerica.com/wp-content/ ... ession.pdf

Healy, H. (2003): Lines of Evidence on the Risks of Suicide with Selective Serotonin Reuptake Inhibitors. Psychother Psychosom 1 April 2003; 72 (2): 71–79. https://doi.org/10.1159/000068691

2002
Shipko, S. (2002): Serotonin Reuptake Inhibitor Withdrawal: Out of the Frying Pan and Into the Fire. Ethical Human Sciences and Services 4(2):83 - 91 https://www.researchgate.net/publicatio ... o_the_Fire

2001
Schweitzer, I., Maguire,K. (2001): Stopping antidepressants. Aust Prescr 2001;24:13-5 http://dx.doi.org/10.18773/austprescr.2001.008

2000
van Weel-Baumgarten, E.M., van den Bosch, W.J., Hekster, Y.A., van den Hoogen, H.J., Zitman, F.G. (2000): Treatment of depression related to recurrence: 10-year follow-up in general practice J Clin Pharm Ther 25(1):61-6 http://www.ncbi.nlm.nih.gov/pubmed/10771465

1999
Llorca PM, Penault F, Lançon C, Dufumier E, Vaiva G. Notion de psychose d'hypersensibilité. Cas particulier de la clozapine [The concept of supersensitivity psychosis. The particular case of clozapine]. Encephale. 1999 Nov-Dec;25(6):638-44. French. PMID: 10668609. https://pubmed.ncbi.nlm.nih.gov/10668609/

1998

Dilsaver, S. C., Alessi, N. E. (1988): Antipsychotic withdrawal symptoms: Phenomenology and pathophysiology. Acta Psychiatrica Scandinavica, 77, 241-246. https://doi.org/10.1111/j.1600-0447.1988.tb05116.x

Goldberg, D., Privett, M., Ustun, B., Simon, G., Linden, M. (1998): The effects of detection and treatment on the outcome of major depression in primary care: a naturalistic study in 15 cities.Br J Gen Pract. 48(437): 1840–1844 http://www.ncbi.nlm.nih.gov/pmc/article ... 198504.pdf

Tranter, R.; Healy, D. (1998): “Neuroleptic Discontinuation Syndromes.” Journal of Psychopharmacology 12 (4): 401-06. DOI: 10.1177/026988119801200412 https://journals.sagepub.com/doi/10.117 ... 9801200412

1997

Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M. (1997): Clinical Risk Following Abrupt and Gradual Withdrawal of Maintenance Neuroleptic Treatment. Arch Gen Psychiatry. 1997;54(1):49–55. doi:10.1001/archpsyc.1997.01830130055011
https://jamanetwork.com/journals/jamaps ... act/497726

1994
Lewander T. (1994): Neuroleptics and the neuroleptic-induced deficit syndrome. Acta Psychiatr Scand Suppl. 380:8-13. http://www.ncbi.nlm.nih.gov/pubmed/7914056

1991
Hoehn-Saric, R; Harris, GJ; Pearlson, GD; Cox, CS; Machlin, SR; Camargo, EE. (1991): A Fluoxetin-Induced Frontal Lobe Syndrome in an Obsessive Compulsive Patient. Journal of Clinical Psychiatry 52 (3): 131-3 http://www.ncbi.nlm.nih.gov/pubmed/2005077

1989
Baker, G.B.; Greenshaw, A.J. (1989): Effects of Long-Term Administration of Antidepressants and Neuroleptics on Receptors in
the Central Nervous System. Cellular and Molecular Neurobiology. 1989 (vol 9, no1): 1-44. http://www.ncbi.nlm.nih.gov/pubmed/2565769

1983
King JR, Hullin RP: (1983): Withdrawal Symptoms from Lithium: Four Case Reports and a Questionnaire Study. British Journal of Psychiatry. 1983;143(1):30-35. https://doi.org/10.1192/bjp.143.1.30

1980
Hodding, G. C., Jann, M., and Ackerman, I. P. (1980): Drug Withdrawal Syndromes A Literature Review. West J Med. 1980 Nov; 133(5): 383–391.
PMCID: PMC1272349 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1272349/